TOFA Dual ACC-PPAR Mechanism Yields 18% Energy Expenditure Rise and Fat-Selective Loss in Obese Mice
Preclinical mouse data position TOFA as a complementary metabolic agent to GLP-1s by raising expenditure rather than cutting intake. Its dual mechanism avoids classic ACC-inhibitor liabilities. Translation to humans requires phase-1 safety and dosing studies.
The preclinical experiments used high-fat diet mice treated with TOFA alone or combined with semaglutide or tirzepatide. TOFA lowered body weight, triglycerides, hepatic steatosis, and glucose levels while preserving muscle; combination arms showed additive gains in all metabolic markers versus monotherapy. Single-agent ACC blockade historically raised triglycerides, yet TOFA avoided this via coordinated PPAR-driven uptake and oxidation, an effect not replicated by separate ACC and PPAR agonists. This suggests the molecule engages an integrated transcriptional response that prior compounds missed. Observational data on GLP-1 muscle loss (up to 40% of weight lost in some trials) underscore the potential value of an energy-expenditure lever, though TOFA remains untested for human pharmacokinetics, off-target effects, or durability beyond 8-12 weeks in rodents.
VITALIS: TOFA IND filing occurs by Q4 2027; phase-1 data will show triglyceride change <5% from baseline at efficacious doses in at least 70% of volunteers.
Sources (2)
- [1]Primary Source(https://www.science.org/doi/10.1126/sciadv.adx1234)
- [2]Supporting Source(https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00215-9/fulltext)